NASDAQ · Biotechnology

MNPR (MNPR) Stock

$107.43 -1.53% NASDAQ: MNPR Healthcare

Valuation

MetricValue
Price$107.43
Market Cap$719.65M
P/E Ratio-32.04
P/B Ratio3.03
P/S Ratio0.00
EPS (TTM)$-1.85
52-Week High$113.57
52-Week Low$29.18
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-0.01%
ROA-0.01%
ROCE-12.32%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio51.36

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-9.0M$-11.0M$-9.0M$-16.0M$-17.0M
Net Profit$-9.0M$-11.0M$-8.0M$-16.0M$-14.0M
EPS$-0.73$-0.83$-0.58$-1.36$-1.85
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$21.0M$13.0M$7.0M$60.0M$141.0M
Total Liabilities$2.0M$3.0M$2.0M$5.0M$3.0M
Cash$20.0M$8.0M$7.0M$46.0M$62.0M
Borrowings$0$0$0$0$0

Latest News

Monopar Therapeutics Begins Rolling Application for ALXN1840 in Wilson Disease MT Newswires · Jul 22, 2026 Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease GlobeNewswire · Jul 22, 2026 Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team GlobeNewswire · Jul 20, 2026 Monopar Therapeutics Says ALXN1840 Receives FDA Rare Pediatric Disease Designation in Wilson Disease MT Newswires · Jun 30, 2026 Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease GlobeNewswire · Jun 30, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-7.0M$-7.0M$-8.0M$-6.0M$-12.0M
Investing Cash Flow$0$-5.0M$5.0M$-14.0M$-63.0M
Financing Cash Flow$0$0$0$0$-36.0M
Net Cash Flow$4.0M$-12.0M$-1.0M$39.0M$16.0M
Free Cash Flow$-7.0M$-7.0M$-8.0M$-6.0M$-12.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-267.12
EV / EBITDA—
FCF Yield-2.32%
Quick Ratio56.04
Interest Coverage—
Return 1Y125.52%
Return 3Y2685.24%
Return 5Y299.16%

Ownership

Insiders Held23.42%
Institutions Held95.19%
Institutions Float Held124.30%
Institutional HolderSharesReport Date
Janus Henderson Group PLC1,317,4102026-03-31
RA Capital Management, L.P.667,2072026-03-31
Saturn V Capital Management LP345,6262026-03-31
Deerfield Management Company, L.P323,7452026-03-31
Blackrock Inc.316,5672026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AKBA $1.31 -0.76% -45.00 $351.42M 0.00%
BCYCBicycle Therapeutics plc $4.22 +0.24% -1.34 $292.84M 0.00%
CMPX $1.89 -4.55% -4.71 $340.37M 0.00%
FDMT $10.09 -0.88% -3.47 $527.47M 0.00%
FULC $3.73 +0.13% -5.17 $201.56M 0.00%

About MNPR

MNPR is led by CEO Chandler D. Robinson, employs 14 people, headquartered in US, publicly traded since 2019.

MNPR stock trades at $107.43 with a market capitalization of $719.65M. The stock is valued at a price-to-earnings (P/E) ratio of -32.04, price-to-book of 3.03, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $29.18 and $113.57, and currently trades 5.4% below its 52-week high.

On profitability, MNPR generates a return on equity (ROE) of -0.01%, return on capital employed of -12.32%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides